What they were paid
Travere Therapeutics Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $70,000 | $137,475 | $412,425 | $0 | $619,900 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Travere Therapeutics, Inc. DEF 14A filed April 6, 2026, accession 0001438533-26-000027, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025Travere Therapeutics pays directors a $50,000 cash retainer and $549,900 in equity.
Committees
FY2025 · as the proxy prints themNominating/Governance · Science & Medical Technology (Chair)
The rest of the Travere Therapeutics board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Eric Dube | Director | $0 |
| Gary Lyons | Independent Director | $638,650 |
| Jeffrey Meckler | Independent Director | $621,900 |
| John A. Orwin | Independent Director | $618,650 |
| Ron Squarer | Independent Director | $609,900 |
| Ruth Williams-Brinkley | Independent Director | $609,275 |
| Sandra Poole | Independent Director | $612,400 |
| Suzanne Bruhn | Independent Director | $616,775 |
| Timothy Coughlin | Independent Director | — |
The full Travere Therapeutics compensation record
free company briefThis page is one director within Travere Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat